Company Filing History:
Years Active: 2018-2024
Title: Joakim Nilsson: Innovator in Polypeptide Engineering
Introduction
Joakim Nilsson, a notable inventor based in Danderyd, Sweden, has made significant contributions to the field of polypeptide engineering. With a total of five patents to his name, Nilsson has demonstrated exceptional skill in developing innovative solutions that hold promise for therapeutic, prognostic, and diagnostic applications.
Latest Patents
Among Nilsson's latest inventions include the IL-IR-I binding polypeptide. This invention focuses on engineered polypeptides that exhibit a strong binding affinity for the interleukin-1 receptor type-I (IL-1R-I). The binding motif associated with this class of polypeptides is defined as EXXXXXXEIXXLPNLXRXQYXAFIXXLXD. Furthermore, these polypeptides can be utilized as therapeutic agents, as well as tools for prognostic and diagnostic purposes.
Additionally, he has developed binding polypeptides with a mutated scaffold. This patent presents a polypeptide sequence identified as EXXXAXXEIXXLPNLXXXQXXAFIXXLXXXPXQSXXLLXE AKKLXXXQ (SEQ ID NO: 55). It describes populations of polypeptide variants based on a common scaffold, enabling the selection of polypeptides with affinities for specific targets.
Career Highlights
Throughout his career, Joakim Nilsson has worked with prominent organizations such as Swedish Orphan Biovitrum AB and Affibody AB. His tenure at these companies has allowed him to hone his expertise in polypeptide research and development, contributing to groundbreaking advancements in the biopharmaceutical sector.
Collaborations
Nilsson's journey in the field of biomedicine has been supported by collaborations with skilled professionals. Notable coworkers include Erik Nordling and Patrik Strömberg, with whom he has shared insights and ideas that have strengthened his innovations.
Conclusion
Joakim Nilsson stands out as a visionary in the arena of polypeptide engineering. His patents reflect his dedication to addressing complex biomedical challenges. As he continues to push the boundaries of innovation, his work holds the potential to make a lasting impact on health and disease treatment strategies.